查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464762

藥物製劑市場：按劑型、技術、治療領域和最終用戶 - 2024-2030 年全球預測

Drug Formulation Market by Dosage Form, Technology, Therapeutic Area, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年藥品製劑市場規模為2.42兆美元，預計2024年將達2.55兆美元，2030年將達3.56兆美元，複合年成長率為5.70%。

藥物製劑是指將活性藥物成分（API）與其他物質結合以形成對患者安全、有效且方便的最終藥物產品的過程。這個複雜的技術過程涉及選擇適當的賦形劑，以確保 API 在人體內的穩定性、生物利用度和最佳性能。慢性病的流行、藥物傳輸技術的進步以及個人化醫療的進步正在增加對更多藥物製劑的需求。儘管潛力巨大，但藥物製劑仍面臨著開發成本高、監管障礙以及創建在口味和給藥方面穩定且患者可接受的製劑的複雜性等挑戰。解決這些限制需要持續投資於研發、採用創新技術並確保監管策略的適應性和效率。奈米技術、緩釋性和生物分解性聚合物等新型藥物傳遞系統的探索可望進一步提高藥物療效和患者依從性，從而有可能改變藥物醫學的模式。

主要市場統計
基準年[2023] 2.42兆美元
預測年份 [2024] 2.55兆美元
預測年份 [2030] 3.56兆美元
複合年成長率（%） 5.70%

劑型：慢性治療中口服製劑的便利性與有效性

吸入製劑設計為直接給藥至呼吸道。它主要用於治療影響肺部的疾病，例如氣喘和慢性阻塞性肺病（COPD）。製劑起效快，全身副作用少。對於需要立即緩解或治療的肺部疾病，此方法是首選。口服製劑如錠劑、膠囊和液體是最常見的給藥型態。這些製劑被設計為透過胃腸道（GI）被全身吸收，並且由於其易於給藥且患者依從性高而被廣泛優選用於慢性疾病。腸胃外製劑繞過胃腸道，主要經由靜脈、肌肉或皮下途徑給藥。腸胃外製劑對於需要快速吸收的治療或胃腸道吸收不良的藥物的給藥至關重要。這對於需要精確控制藥物生物有效性的急救藥物、生技藥品和治療至關重要。外用產品包括塗布在皮膚表面的霜劑、軟膏、凝膠和貼片。它們主要用於局部治療，具有最大限度減少全身暴露的優點。透過局部給藥來治療皮膚病和疼痛的理想選擇。

最終用戶：藥廠加大藥物研發投資

學術研究機構主要致力於開發創新製劑和藥物傳遞系統。此外，人們經常尋找具有​​潛在治療作用的新化合物。合約藥物開發和受託製造廠商（CDMO）在藥物製劑領域發揮著至關重要的作用，提供從藥物開發到製造的廣泛服務。 CDMO 迎合注重彈性、擴充性和上市速度的製藥公司，旨在將這些方面外包以專注於核心競爭力。醫院和診所是透過藥物管理致力於病患照護的主要最終使用者。他們喜歡安全、有效且能提高病患依從性的藥物。該行業對能夠簡化給藥方案和改善治療效果的製劑特別感興趣。製藥公司是藥物製劑產業的核心參與者，從事藥物的發現、開發、生產和銷售。

區域洞察

在美洲，尤其是美國，由於大型製藥公司的存在以及以 FDA 為中心的完善的法律規範，非常重視創新的藥物製劑技術。因此，人們對研發（R&D）進行了積極投資，重點關注生技藥品和緩釋性等複雜製劑。此外，先進的製造設備增強了美洲的生產能力，使新配方能夠快速擴展。由於醫療保健成本不斷上升、對學名藥的需求不斷成長以及法規結構不斷完善，亞太地區正在迅速成為藥品製劑市場的主要參與者。印度和中國等國家利用其具有成本效益的製造和龐大的科學人才庫，在學名藥生產方面處於領先地位。歐洲、中東和非洲地區是一個成熟的市場，非常注重高品質的藥物配方和嚴格的監管標準，特別是在歐盟 (EU) 國家。私人公司是先進給藥系統和個人化醫療領域的領導者，並得到強大的醫療保健系統以及政府和私人對藥物研發的大量投資的支持。

FPNV定位矩陣

FPNV定位矩陣對於評估藥品製劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對藥物製劑市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 藥品製劑市場的市場規模與預測為何？

2.在藥物製劑市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.藥品製劑市場的技術趨勢和法規結構是什麼？

4.藥品製劑市場主要廠商的市場佔有率為何？

5. 進入藥品製劑市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和有效治療的需要
      • 政府鼓勵藥物開發和發現的努力
      • 個人化醫療和治療方法的興起
    • 抑制因素
      • 因不利事件而召回
    • 機會
      • 藥物傳輸和給藥技術的進步
      • 學名藥開發CDMO投資
    • 任務
      • 藥物配方的複雜開發與加工
  • 市場區隔分析
    • 劑型：口服製劑在慢性治療的便利性與有效性
    • 最終用戶：藥廠加大藥物研發投資
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章以劑型分類的藥物製劑市場

  • 吸入製劑
  • 口服製劑
  • 腸外製劑
  • 局部製劑

第7章藥物製劑市場：依技術分類

  • 速效製劑
  • 微脂體體製劑
  • 微球製劑
  • 改良釋放製劑
  • 奈米配方
  • 自乳化給藥系統
  • 固體分散體製劑

第8章依治療領域分類的藥物製劑市場

  • 心血管
  • 中樞神經系統
  • 皮膚科
  • 內分泌學
  • 胃
  • 免疫學
  • 感染疾病
  • 腫瘤學
  • 眼科
  • 疼痛管理
  • 呼吸系統

第9章藥物製劑市場：依最終使用者分類

  • 學術/研究機構
  • 合約開發和製造組織
  • 醫院/診所
  • 製藥公司

第10章美洲藥物製劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物製劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲藥品製劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Glenmark 在印度推出針對 2 型糖尿病患者的三重藥物配方
    • Neurocrine Biosciences 宣布美國FDA 已接受其 INGREZZA（Valbenazine）口服顆粒噴劑新藥申請
    • 默克和 XtalPi 合作利用人工智慧技術最佳化藥物處方
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-351BAD50373D

[193 Pages Report] The Drug Formulation Market size was estimated at USD 2.42 trillion in 2023 and expected to reach USD 2.55 trillion in 2024, at a CAGR 5.70% to reach USD 3.56 trillion by 2030.

Drug formulation refers to the process through which active pharmaceutical ingredients (APIs) are combined with other substances to create a final medicinal product that is safe, effective, and convenient for patients to use. This technical and intricate process involves choosing suitable excipients to ensure the stability, bioavailability, and optimal performance of the API in the human body. The prevalence of chronic diseases, advancements in drug delivery technologies, and the escalation of personalized medicine have been elevating the need for more drug formulations. Despite the immense potential, drug formulation faces challenges such as the high cost of development, regulatory hurdles, and the complexity of creating formulations that are both stable and acceptable to patients in terms of taste and administration method. Addressing these restraints requires continuous investment in R&D, adopting innovative technologies, and ensuring regulatory strategies are adaptable and efficient. The exploration of novel drug delivery systems such as nanotechnology, sustained-release formulations, and biodegradable polymers is expected to further enhance drug efficacy and patient compliance, potentially transforming the landscape of pharmaceutical care.

KEY MARKET STATISTICS
Base Year [2023] USD 2.42 trillion
Estimated Year [2024] USD 2.55 trillion
Forecast Year [2030] USD 3.56 trillion
CAGR (%) 5.70%

Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments

Inhalation formulations are designed for direct delivery to the respiratory tract. They are primarily used for conditions affecting the lungs, such as asthma and chronic obstructive pulmonary disease (COPD). This delivery method offers rapid onset of action and reduced systemic side effects. It is preferred for pulmonary conditions requiring fast relief or management. Oral formulations, including tablets, capsules, and liquids, are the most common form of drug administration. They are designed for systemic absorption through the gastrointestinal (GI) tract and were widely preferred for chronic diseases due to ease of administration and patient compliance. Parenteral formulations are administered bypassing the GI tract, mainly through intravenous, intramuscular, and subcutaneous routes. They are critical for treatments that require rapid absorption or when the drug is poorly absorbed from the gut. It is essential for emergency medicines, biologics, and treatments requiring precise control over drug bioavailability. Topical formulations include creams, ointments, gels, and patches applied to the skin's surface. They are primarily used for localized treatment, offering the advantage of minimizing systemic exposure. It is ideal for dermatological conditions and pain management through localized drug delivery.

End User: Rising investments in drug developments by pharmaceutical companies

Academic and research institutions primarily focus on developing innovative formulations and drug delivery systems. They often explore novel compounds with potential therapeutic benefits. Contract development & manufacturing organizations (CDMOs) are pivotal in the drug formulation sector, providing a wide range of services from drug development to manufacturing. They focus on flexibility, scalability, and speed-to-market, catering to pharmaceutical companies that aim to outsource these aspects to focus on their core competencies. Hospitals and clinics are the primary end users focusing on patient care through the administration of drugs. Their preference leans towards pharmaceuticals that are safe, effective, and offer better patient compliance. This sector is particularly interested in formulations that can simplify dosing regimes and enhance therapeutic outcomes. Pharmaceutical companies are central to the drug formulation industry, engaged in the discovery, development, production, and marketing of medications.

Regional Insights

In the Americas, especially the United States, there is a significant emphasis on innovative drug formulation technologies due to the presence of major pharmaceutical companies and a well-established regulatory framework led by the FDA. This promotes a high level of investment in research and development (R&D), focusing on complex formulations such as biologics and sustained-release drugs. The production capacity in the Americas is also bolstered by advanced manufacturing facilities, enabling rapid scalability of new formulations. APAC is rapidly emerging as a key player in the drug formulation market, driven by increasing healthcare expenditure, growing demand for generic medicines, and improvements in regulatory frameworks. Countries like India and China are leading in the production of generics, leveraging cost-effective manufacturing and a large pool of scientific talent. The EMEA region presents a mature market with a strong focus on high-quality drug formulations and stringent regulatory standards, especially in the European Union (EU) countries. Companies in the EMEA region are leading in advanced drug delivery systems and personalized medicine, supported by robust healthcare systems and significant government and private investment in pharmaceutical R&D.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug Formulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug Formulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dosage Form
    • Inhalation Formulations
      • Dry Powder Inhaler
      • Nebulizer
      • Pressurized Metered Dose Inhaler
    • Oral Formulations
      • Capsules
      • Gummies
      • Lozenges & Pastilles
      • Powders & Granules
      • Tablets
    • Parenteral Formulations
      • Emulsions
      • Gels
      • Powders
      • Solutions
      • Suspensions
    • Topical Formulations
      • Creams, Lotions, & Foams
      • Gels, Tinctures, & Powders
      • Ointments & Oils
      • Pastes
      • Sprays & Patches
  • Technology
    • Immediate-Release Formulations
    • Liposomal Formulations
    • Microsphere Formulations
    • Modified-Release Formulations
    • Nanoformulations
    • Self-Emulsifying Drug Delivery Systems
    • Solid Dispersion Formulations
  • Therapeutic Area
    • Cardiovascular
    • Central Nervous System
    • Dermatology
    • Endocrinology
    • Gastrointestinal
    • Immunology
    • Infectious Diseases
    • Oncology
    • Ophthalmology
    • Pain Management
    • Respiratory
  • End User
    • Academic & Research Institutions
    • Contract Development & Manufacturing Organizations
    • Hospitals & Clinics
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Drug Formulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug Formulation Market?

3. What are the technology trends and regulatory frameworks in the Drug Formulation Market?

4. What is the market share of the leading vendors in the Drug Formulation Market?

5. Which modes and strategic moves are suitable for entering the Drug Formulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
      • 5.1.1.2. Government initiatives encouraging drug development and discovery
      • 5.1.1.3. Rise of personalized and tailored medicine and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of drugs and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery and dosage technologies
      • 5.1.3.2. Investments in CDMOs to develop generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex development and processing of drug formulations
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
    • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Drug Formulation Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Inhalation Formulations
  • 6.3. Oral Formulations
  • 6.4. Parenteral Formulations
  • 6.5. Topical Formulations

7. Drug Formulation Market, by Technology

  • 7.1. Introduction
  • 7.2. Immediate-Release Formulations
  • 7.3. Liposomal Formulations
  • 7.4. Microsphere Formulations
  • 7.5. Modified-Release Formulations
  • 7.6. Nanoformulations
  • 7.7. Self-Emulsifying Drug Delivery Systems
  • 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrinology
  • 8.6. Gastrointestinal
  • 8.7. Immunology
  • 8.8. Infectious Diseases
  • 8.9. Oncology
  • 8.10. Ophthalmology
  • 8.11. Pain Management
  • 8.12. Respiratory

9. Drug Formulation Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Development & Manufacturing Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Formulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
    • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
    • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DRUG FORMULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 94. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 95. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 96. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 97. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 98. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 99. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 100. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 101. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 104. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 105. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 106. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 107. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 108. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 109. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 110. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 111. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 112. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 113. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 114. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 115. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 116. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 117. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 118. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 119. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 120. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 121. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 124. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 125. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 126. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 127. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 128. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 129. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 130. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 131. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 132. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 133. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 134. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 135. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 136. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 137. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 138. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 139. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 142. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 143. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 144. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 145. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 146. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 147. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 148. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 149. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 150. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 151. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 152. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 153. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 154. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 155. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 158. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 159. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 160. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 161. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 162. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 163. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 164. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 165. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 166. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 167. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 168. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 169. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 170. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 171. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 174. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 175. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 178. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 179. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 180. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 181. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 182. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 183. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 184. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 185. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 186. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 187. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 190. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 191. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 195. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 196. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 197. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 198. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 199. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 200. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 201. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 202. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 203. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 206. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 207. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 208. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 229. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 230. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 231. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 232. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 233. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 234. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 235. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 236. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 237. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 238. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 239. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 242. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 243. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 246. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 247. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 248. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 249. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 250. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 251. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 252. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 253. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 254. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 255. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 256. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 257. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 258. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 259. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 262. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 263. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 264. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 265. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 266. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 267. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 268. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 269. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 274. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 275. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 278. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 279. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 280. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 281. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 282. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 283. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 284. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 285. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 286. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 287. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 290. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 291. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 292. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 293. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 294. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 295. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 296. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 297. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 298. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 299. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 300. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 301. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 302. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 303. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 304. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 305. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 306. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 307. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 310. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 311. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 312. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 313. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 314. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 315. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 316. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 317. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 318. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 319. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 322. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 323. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 326. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 328. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 329. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 330. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 331. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 332. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 333. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 334. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 335. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 336. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 337. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 338. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILL